Table 3.

Comparison of 2012 versus 2019 Safety Outcomes and Quality of Safety Reporting Findings.

Safety Outcomes	2012 SafeCell SR		2018 SafeCell SR Update
	# of RCTs*	Findings (RR, 95% CI)	# of RCTS*	Findings (RR, 95% CI)
Infusional toxicity- non-fever	4/8	2·01 (0·34–11·77)	32/55	1·16 (0·70–1·91)
Infusional toxicity- fever	4/8	9·28 (2·02–42·71)	19/55	2·48 (1·27–4·86)
Infection	4/8	1·09 (0·61–1·94)	27/55	0·99 (0·81–1·21)
Malignancy or ectopic tissue formation	4/8	2·21 (0·85–5·74)	19/55	0·93 (0·60–1·45)
Mortality	8/8	1·22 (0·71–2·10)	40/55	0·78 (0·65–0·94)
Thrombotic or embolic events	4/8⁎⁎	2·71 (0·86–8·48)	24/55	1·14 (0·67–1·95)
Quality of Safety Reporting	# of RCTs*	Findings (%)	# of RCTs*	Findings (%)
A priori plan to monitor adverse events	3/8	37·5%	43/55	78·2%

^⁎That reported the adverse event.

^⁎⁎Original review did not report on this outcome, but event rate is inserted for comparison purposes.